Novan, Inc. – NASDAQ:NOVN

Novan stock price today

$0.089
+0.03
+78.8%
Financial Health
0
1
2
3
4
5
6
7
8
9

Novan stock price monthly change

-92.75%
month

Novan stock price quarterly change

-95.69%
quarter

Novan stock price yearly change

-98.34%
year

Novan key metrics

Market Cap
2.63M
Enterprise value
20.45M
P/E
-1.03
EV/Sales
0.64
EV/EBITDA
-0.37
Price/Sales
0.90
Price/Book
6.26
PEG ratio
-0.01
EPS
0.12
Revenue
24.71M
EBITDA
-32.08M
Income
999K
Revenue Q/Q
58.35%
Revenue Y/Y
522.98%
Profit margin
-89.05%
Oper. margin
-198.69%
Gross margin
67.9%
EBIT margin
-198.69%
EBITDA margin
-129.83%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Novan stock price history

Novan stock forecast

Novan financial statements

Novan, Inc. (NASDAQ:NOVN): Profit margin
Jun 2022 6.15M -9.01M -146.53%
Sep 2022 5.09M -2.44M -47.91%
Dec 2022 10.46M 26.57M 253.88%
Mar 2023 2.99M -14.11M -471.26%
Novan, Inc. (NASDAQ:NOVN): Debt to assets
Jun 2022 114392000 102.14M 89.29%
Sep 2022 83270000 76.51M 91.88%
Dec 2022 90330000 85.72M 94.9%
Mar 2023 79793000 82.62M 103.54%
Novan, Inc. (NASDAQ:NOVN): Cash Flow
Jun 2022 -11.11M -1.87M 14.79M
Sep 2022 -9.43M -3.00M -9.96M
Dec 2022 -11.10M -1.06M 10.63M
Mar 2023 -4.25M -23K 4.09M

Novan alternative data

Novan, Inc. (NASDAQ:NOVN): Employee count
Aug 2023 90
Sep 2023 90
Oct 2023 90
Nov 2023 90
Dec 2023 90
Jan 2024 90
Feb 2024 90
Mar 2024 90
Apr 2024 90
May 2024 90
Jun 2024 90
Jul 2024 90

Novan other data

2.06% -5.25%
of NOVN is owned by hedge funds
454.27K -1.33M
shares is hold by hedge funds

Novan, Inc. (NASDAQ:NOVN): Insider trades (number of shares)
Period Buy Sel
Mar 2022 24000 0
Apr 2022 1000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
GAY JOHN M. officer: Chief Financial Officer
Common Stock 65,000 N/A N/A
Option
GAY JOHN M. officer: Chief Financial Officer
Restricted Stock Units 65,000 N/A N/A
Option
GEER W KENT director
Common Stock 36,101 N/A N/A
Option
GEER W KENT director
Restricted Stock Units 36,101 N/A N/A
Option
SANDERS MACHELLE director
Common Stock 36,101 N/A N/A
Option
SANDERS MACHELLE director
Restricted Stock Units 36,101 N/A N/A
Option
BIERMAN JAMES L director
Common Stock 36,101 N/A N/A
Option
BIERMAN JAMES L director
Restricted Stock Units 36,101 N/A N/A
Option
KEEGAN ROBERT J director
Common Stock 36,101 N/A N/A
Option
KEEGAN ROBERT J director
Restricted Stock Units 36,101 N/A N/A
Patent
Application
Filling date: 18 Feb 2022 Issue date: 2 Jun 2022
Application
Filling date: 20 Aug 2021 Issue date: 21 Apr 2022
Grant
Filling date: 1 Mar 2019 Issue date: 29 Mar 2022
Grant
Filling date: 5 Feb 2019 Issue date: 29 Mar 2022
Application
Filling date: 3 Sep 2021 Issue date: 23 Dec 2021
Application
Filling date: 25 May 2021 Issue date: 11 Nov 2021
Grant
Filling date: 13 Apr 2017 Issue date: 9 Nov 2021
Application
Filling date: 28 Jun 2021 Issue date: 21 Oct 2021
Grant
Filling date: 29 Aug 2019 Issue date: 21 Sep 2021
Grant
Filling date: 28 Feb 2013 Issue date: 3 Aug 2021
Insider Compensation
Ms. Paula Brown Stafford M.P.H. (1965) Pres, Chief Executive Officer & Chairwoman
$897,860
Mr. John M. Gay CPA (1976) Chief Financial Officer & Corporation Sec.
$408,030
Monday, 17 July 2023
Monday, 15 May 2023
Seeking Alpha
Monday, 8 May 2023
GlobeNewsWire
Thursday, 23 March 2023
GlobeNewsWire
Tuesday, 14 March 2023
GlobeNewsWire
Wednesday, 18 January 2023
GlobeNewsWire
Tuesday, 15 November 2022
Seeking Alpha
Thursday, 11 August 2022
Seeking Alpha
Thursday, 4 August 2022
GlobeNewsWire
Thursday, 19 May 2022
GlobeNewsWire
Monday, 16 May 2022
Seeking Alpha
Friday, 6 May 2022
GlobeNewsWire
Tuesday, 22 February 2022
Seeking Alpha
Tuesday, 15 February 2022
GlobeNewsWire
Thursday, 23 September 2021
GlobeNewsWire
Monday, 20 September 2021
GlobeNewsWire
Thursday, 9 September 2021
GlobeNewsWire
Wednesday, 8 September 2021
GlobeNewsWire
Tuesday, 7 September 2021
GlobeNewsWire
Thursday, 2 September 2021
GlobeNewsWire
  • What's the price of Novan stock today?

    One share of Novan stock can currently be purchased for approximately $0.09.

  • When is Novan's next earnings date?

    Unfortunately, Novan's (NOVN) next earnings date is currently unknown.

  • Does Novan pay dividends?

    No, Novan does not pay dividends.

  • How much money does Novan make?

    Novan has a market capitalization of 2.63M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 736.61% to 23.61M US dollars.

  • What is Novan's stock symbol?

    Novan, Inc. is traded on the NASDAQ under the ticker symbol "NOVN".

  • What is Novan's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Novan?

    Shares of Novan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Novan's key executives?

    Novan's management team includes the following people:

    • Ms. Paula Brown Stafford M.P.H. Pres, Chief Executive Officer & Chairwoman(age: 60, pay: $897,860)
    • Mr. John M. Gay CPA Chief Financial Officer & Corporation Sec.(age: 49, pay: $408,030)
  • How many employees does Novan have?

    As Jul 2024, Novan employs 90 workers.

  • When Novan went public?

    Novan, Inc. is publicly traded company for more then 8 years since IPO on 21 Sep 2016.

  • What is Novan's official website?

    The official website for Novan is novan.com.

  • Where are Novan's headquarters?

    Novan is headquartered at 4020 Stirrup Creek Drive, Durham, CA.

  • How can i contact Novan?

    Novan's mailing address is 4020 Stirrup Creek Drive, Durham, CA and company can be reached via phone at +91 94858080.

Novan company profile:

Novan, Inc.

novan.com
Exchange:

NASDAQ

Full time employees:

90

Industry:

Biotechnology

Sector:

Healthcare

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

4020 Stirrup Creek Drive
Durham, CA 27703

CIK: 0001467154
ISIN: US66988N2053
CUSIP: 66988N205